Personalized benefit-risk assessments combining clinical trial and real-world data provide further insights into which patients may benefit most from therapy: Demonstration for a new oral antiplatelet therapy.
Cathy Anne PintoTommi TervonenKevin MarshDimitra LambrelliAnna SchultzeAndrew TershakovecJohanna HyacintheThibaud PrawitzTarek A HammadPublished in: Pharmacoepidemiology and drug safety (2019)
Personalized B-R assessments are feasible and clinically valuable and can be used to better predict who would benefit most from therapy.
Keyphrases
- antiplatelet therapy
- clinical trial
- end stage renal disease
- acute coronary syndrome
- percutaneous coronary intervention
- chronic kidney disease
- newly diagnosed
- ejection fraction
- peritoneal dialysis
- prognostic factors
- electronic health record
- stem cells
- open label
- coronary artery disease
- randomized controlled trial
- mesenchymal stem cells
- phase ii
- cell therapy
- bone marrow
- patient reported
- double blind
- artificial intelligence
- replacement therapy
- breast cancer risk